The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth…
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report…
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
Clarivate Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…